PT003 is a twice-daily fixed-dose mix of glycopyrronium.

PublishedJanuary 5, 2018

AstraZeneca announces positive Stage III top-line outcomes for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD Today announced positive top-line outcomes from the Stage III PINNACLE program AstraZeneca, including two pivotal 24-week research to research the potential of PT003 to boost lung function in individuals with Chronic Obstructive Pulmonary Disease silagra . PT003 is a twice-daily fixed-dose mix of glycopyrronium, a long-performing muscarinic antagonist and formoterol fumarate, a long-performing beta-2 agonist .

Stage IIb trial results present significant improvement in Hamilton Melancholy Rating Scale ratings on the result on depressive symptoms in individuals who did not react adequately to citalopram monotherapy. These outcomes indicate that TC-5214 offers competitive advantages in efficacy over current and emerging medications for treatment resistant despair. Related StoriesResearchers determine potential brain-centered biomarker for depressive symptomsResilience-based programs might help LGBT youths deal with negative stressorsStudy displays link between exercise and depression in sufferers at risk for cardiovascular disease’Stage IIb trials demonstrated the efficacy of TC-5214 as an augmentation therapy for main depressive disorder; should Stage III trials demonstrate both efficacy and tolerability, TC-5214 will have a substantial market advantage and could earn blockbuster product sales in the main depressive disorder marketplace,’ stated Decision Assets’ Analyst Alana Simorellis, Ph.D.